stockrow
Friday 6 November 2026
Export KPRX’s income statement to Excel — free account
Kiora Pharmaceuticals, Inc.
KPRX Healthcare Biotechnology
Kiora Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $16.0 million.
- EPS
- +37.0%
- Free cash flow
- +50.1%
Quarter to June 2026, against a year earlier
1.42
0.08
−5.33%
Follow KPRX
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
8.54 | 5.62 | 6.19 | 8.33 | |
Current Ratio |
8.79 | 5.99 | 6.68 | 8.97 | |
Net Debt/EBITDA |
24.72 | 2.34 | 5.55 | 7.64 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(47.50) | 0.33 | 1.31 | 0.91 | |
Capex/Depreciation |
(0.04) | (7.45) | (0.47) | (2.20) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.22 | 0.09 | 0.10 | 0.09 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.30) | (0.52) | (0.76) | (0.31) | |
Capex per Share |
0.00 | (0.02) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.30) | (0.54) | (0.76) | (0.31) | |
Cash per Share |
4.58 | 4.10 | 3.32 | 2.73 | |
Shareholders Equity per Share |
5.30 | 3.87 | 3.34 | 2.73 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.30 | 3.87 | 3.34 | 2.73 | |
Free Cash Flow |
(1.27) | (2.26) | (3.17) | (1.92) | |
Working Capital |
20.11 | 18.12 | 15.88 | 18.89 | |
Capital Expenditures |
0.00 | (0.08) | 0.00 | (0.02) | |
Net Current Asset Value |
15.24 | 13.62 | 11.39 | 14.34 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.41 | 2.09 | 2.76 | 3.01 | |
Average Payables |
0.45 | 0.74 | 0.77 | 0.25 | |
Average Assets |
34.19 | 30.37 | 27.62 | 27.86 | |
Average Common Equity |
26.22 | 20.94 | 18.82 | 19.49 |
Columns are period end dates · fundamentals updated 26 Oct 2026